Minhai COVID-19 vaccine

Minhai COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	KCONVAC (Chinese: 可维克; pinyin: Kěwéikè)
Routes of; administration	Intramuscular
Legal status
Legal status	Full list of Minhai vaccine authorizations;

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Clinical trials[]

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.^[1]

Later, KCONVAC started phase II trials with 1,000 participants in China.^[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.^[3]

Children and adolescents trials[]

In August 2021, KCONVAC started phase I trials with 84 participants in China.^[4]

In September, KCONVAC started phase II trials with 480 participants in China.^[5]

Authorizations[]

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.^[6]

References[]

^ "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
^ "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
^ "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 20 April 2021. Retrieved 22 April 2021.
^ "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.
^ "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.
^ Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.

Scholia has a profile for Minhai COVID-19 vaccine (Q106522079).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by .

[1] "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.

[2] "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.

[3] "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 20 April 2021. Retrieved 22 April 2021.

[4] "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.

[5] "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.

[6] Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.

[1]

[2]

[3]

[4]

[5]

[6]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments China US Fake treatments Protests US Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths Zero-COVID National responses Africa China European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Vaccine candidates CoronaVac Covaxin Convidecia Janssen Moderna Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Canadian meat US meat Food security Journalism Music Performing arts Retail Shipping Sports Ireland Philippines Television US programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Ireland Death rates by country Disability Domestic violence Emergency evacuations Education Female Ghana Ireland UK US Environment Hospitals Language LGBT community Long-term care Mental health Symptoms Migration Military Notable deaths South Africa Other health issues Politics Ireland Malaysia Russia Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Society Ireland Malaysia New Zealand Russia UK US Strikes Suicides Telehealth Xenophobia and racism
COVID-19 portal
v t